FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder

November 30, 2017 – The U.S. Food and Drug Administration today approved buprenorphine, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days … (leggi tutto)